|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08189 TEDA BIOMEDICAL
Nominal 
0.280 +0.010 (+3.704%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 397,998 | -11.492% | 449,676 | 476,385 | 369,355 | 358,752 |
| Cost of Sales | (376,632) | -13.074% | (433,281) | (430,780) | (328,963) | (323,756) |
| Gross Profit | 21,366 | 30.316% | 16,395 | 45,605 | 40,392 | 34,996 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | (3,158) | -- | (8,755) | |
| Change in FV & Impairment on Others | (1,707) | 442.537% | (315) | (22,945) | (14,380) | (24,331) | |
| Profit / (Loss) on Disposal | -- | -- | 5,912 | -- | -- | 1,919 | |
| Other Non-operating Items | -- | -- | -- | -- | 297 | (1,491) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 1,001 | (1,938) | (4,953) | |
| Profit / (Loss) before Taxation | (12,012) | -54.662% | (26,495) | (44,839) | (50,001) | (88,816) | |
| Taxation | 1,044 | -- | (151) | 55 | (363) | 5 | |
| Profit / (Loss) from Discontinued Operations | (5,602) | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (3,589) | 145.806% | (1,460) | 2,529 | 2,365 | 4,189 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (20,160) | -28.273% | (28,106) | (42,255) | (47,998) | (84,622) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 4,923 | -12.694% | 5,639 | 5,036 | 805 | 4,094 |
| Depreciation & Amortisation | 10,945 | -28.884% | 15,390 | 9,513 | 7,104 | 14,607 |
| Directors' Emoluments | 1,120 | -19.206% | 1,387 | 1,591 | 1,711 | 1,774 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified (Modified Report) | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -1.060 | -28.378% | -1.480 | -2.230 | -2.530 | -4.470 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.007) | -- | (0.007) | (0.004) | 0.019 | (0.002) |
| NBV per share ($) | 0.026 | -- | 0.037 | 0.053 | 0.076 | 0.101 |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -4,123,183 |
| %Change | -63.350% |
| EPS / (LPS) | RMB -0.002 |
| NBV Per Share (¥) | RMB 0.024 |